title: Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction.
abstract: BACKGROUND
  There are limited data regarding implantable cardioverter defibrillator (ICD) therapy in postinfarction women with severe left ventricular dysfunction. The aim of this study was to evaluate the risk of cardiac events and effects of ICD therapy in women as compared to men enrolled in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II).
  
  
  RESULTS
  Among 1,232 patients enrolled in MADIT II, there were 192 (16%) women and 1,040 (84%) men. When compared to men, women had an increased frequency of NYHA class > or =II (70 vs 63%; P = 0.067), hypertension (60% vs 52%; P = 0.047), diabetes (42% vs 34%; P = 0.027), and LBBB (25% vs 17%; P = 0.011), and less frequent CABG surgery (42% vs 60%; P < 0.001). The 2-year cumulative mortality in patients randomized to conventional therapy was not significantly different in women and men (30% and 20%, respectively; P = 0.19). Adjusting for relevant clinical covariates, the hazard ratios for ICD effectiveness were similar in women (0.57; 95% CI = 0.28-1.18; P = 0.132) and men (0.66; 95% CI = 0.48-0.91; P = 0.011). The risk of appropriate ICD therapy for VT/VF was lower in women than in men (hazard ratio = 0.60 for female vs male gender; 95% CI = 0.37-0.98; P = 0.039).
  
  
  CONCLUSIONS
  MADIT II women had similar mortality and similar ICD effectiveness when compared to men. MADIT II women with ICDs had a lower risk of arrhythmic events with fewer episodes of ventricular tachycardia than men.
authors.affiliation: Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642-8653, USA. wojciech_zareba@urmc.rochester.edu
authors.forename: Wojciech
authors.initials: W
authors.lastname: Zareba
authors.forename: Arthur J
authors.initials: AJ
authors.lastname: Moss
authors.forename: W
authors.initials: W
authors.lastname: Jackson Hall
authors.forename: David J
authors.initials: DJ
authors.lastname: Wilber
authors.forename: Jeremy N
authors.initials: JN
authors.lastname: Ruskin
authors.forename: Scott
authors.initials: S
authors.lastname: McNitt
authors.forename: Mary
authors.initials: M
authors.lastname: Brown
authors.forename: Hongyue
authors.initials: H
authors.lastname: Wang
mesh_terms: D000368:Aged; D017147:Defibrillators, Implantable; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology*; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D017180:Tachycardia, Ventricular / Q000503:physiopathology*; D013997:Time Factors; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000401:mortality / Q000628:therapy*